Syndax Pharmaceuticals, Inc.

NASDAQ•SNDX

CEO: Mr. Michael A. Metzger M.B.A.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2016-03-02

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Contact Information

35 Gatehouse Drive, Building D Floor 3, Waltham, MA, 02451, United States

781-419-1400

www.syndax.com

Market Cap

$1.86B

P/E (TTM)

-6.5

19.9

Dividend Yield

52W High

$22.73

52W Low

$8.58

52W Range

91%

Rank58Top 85.6%

2.3

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 2.3 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$68.48M+0.00%

4-Quarter Trend

EPS

-$0.78+0.00%

4-Quarter Trend

FCF

-$69.54M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Massive Revenue Surge Total revenue reached $172.35M in 2025, up 627.8% from $23.68M in 2024, driven by product sales.

Product Revenue Established Net product revenue hit $124.84M in 2025, up from $7.68M in 2024, following Revuforj U.S. launch.

Collaboration Revenue Streams Collaboration revenue, net, totaled $42.37M in 2025 from Niktimvo co-commercialization with Incyte partner.

Net Loss Narrowed Net loss improved by $33.34M to $285.42M in 2025, reflecting initial commercial revenue impact.

Risk Factors

Commercialization Execution Risk Success heavily depends on successful U.S. commercialization of Revuforj and Niktimvo; no guarantee of expected revenue timing.

High Operating Expense R&D expenses were $258.78M in 2025; SG&A rose $58.80M supporting new product launches.

Continued Net Losses Company incurred net losses since inception (except 2021); anticipates continued losses for the near future.

Intellectual Property Defense Success depends on maintaining patent rights; litigation risk exists regarding owned and licensed IP portfolios.

Outlook

Advance Revumenib Pipeline Continue advancing Revumenib frontline trials in combination therapies for NPM1m and KMT2Ar AML indications.

Expand Niktimvo Indications Advance clinical development for Niktimvo in newly diagnosed cGVHD patients and explore IPF treatment proof-of-concept.

Strategic Partner Leverage Leverage expertise with Incyte for axatilimab and seek external partners for U.S. Revuforj commercialization evaluation.

Future Funding Requirements Future capital needs depend on growth rate, trial costs, and regulatory outcomes; potential dilution if financing secured.

Peer Comparison

Revenue (TTM)

SNDX

$172.35M

+627.8%

IMTX

$93.54M

-26.7%

SYRE

$90.49M

+0.0%

Gross Margin (Latest Quarter)

SNDX

102.3%

-13.9pp

IMTX

100.0%

+0.0pp

ATAI

100.0%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
PRAX	$6.73B	-23.6	-58.7%	0.0%
WVE	$2.50B	-11.8	-85.7%	2.8%
SYRE	$2.42B	-89.3	-29.4%	0.0%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

50.6%

Strong Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 4, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data